Focus Partners Advisor Solutions LLC Invests $2.63 Million in Illumina, Inc. $ILMN

Focus Partners Advisor Solutions LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 14,946 shares of the life sciences company’s stock, valued at approximately $2,628,000.

A number of other institutional investors have also made changes to their positions in ILMN. Elyxium Wealth LLC acquired a new position in Illumina during the fourth quarter worth $25,000. TD Waterhouse Canada Inc. acquired a new stake in Illumina in the 4th quarter valued at $26,000. Laurel Wealth Advisors LLC acquired a new stake in Illumina in the 4th quarter valued at $26,000. Activest Wealth Management increased its stake in Illumina by 671.9% in the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after buying an additional 215 shares during the last quarter. Finally, Quarry LP bought a new stake in Illumina during the 3rd quarter worth about $32,000. Institutional investors own 89.42% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Scott D. Ericksen sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total value of $225,150.00. Following the completion of the sale, the chief accounting officer directly owned 14,946 shares of the company’s stock, valued at $2,243,394.60. This trade represents a 9.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of Illumina stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the transaction, the director owned 2,372,694 shares of the company’s stock, valued at $474,776,069.40. This represents a 16.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 1,415,351 shares of company stock worth $255,966,311. Company insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ILMN shares. Piper Sandler restated an “overweight” rating and set a $225.00 price objective (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. Canaccord Genuity Group upped their target price on Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a report on Monday, August 3rd. Guggenheim increased their price target on Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Evercore restated an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Finally, Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a research report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $188.40.

Illumina Stock Performance

Shares of ILMN stock opened at $190.89 on Friday. The company has a fifty day moving average price of $183.78 and a two-hundred day moving average price of $150.56. Illumina, Inc. has a one year low of $88.00 and a one year high of $207.00. The stock has a market cap of $28.82 billion, a P/E ratio of 35.61, a P/E/G ratio of 2.69 and a beta of 1.45. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. Illumina’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.